Announcement • Jun 30
Jiangsu Sihuan Bioengineering Co., Ltd to Report First Half, 2026 Results on Aug 21, 2026 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report first half, 2026 results on Aug 21, 2026 New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Announcement • Apr 20
Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 08, 2026 Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 08, 2026, at 14:30 China Standard Time. Location: Units 05 and 06, 41F, No. 2, Binjiang East Road, Jiangyin, Jiangsu China Announcement • Mar 31
Jiangsu Sihuan Bioengineering Co., Ltd to Report Q1, 2026 Results on Apr 27, 2026 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Jiangsu Sihuan Bioengineering Co., Ltd to Report Fiscal Year 2025 Results on Apr 18, 2026 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report fiscal year 2025 results on Apr 18, 2026 Board Change • Dec 13
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-independent director Linfu Wei was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2025 earnings released: CN¥0.003 loss per share (vs CN¥0.003 loss in 3Q 2024) Third quarter 2025 results: CN¥0.003 loss per share (in line with 3Q 2024). Revenue: CN¥112.5m (up 124% from 3Q 2024). Net loss: CN¥2.60m (loss narrowed 27% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Jiangsu Sihuan Bioengineering Co., Ltd to Report Q3, 2025 Results on Oct 25, 2025 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Aug 27
Second quarter 2025 earnings released: EPS: CN¥0.006 (vs CN¥0.008 loss in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.006 (up from CN¥0.008 loss in 2Q 2024). Revenue: CN¥138.1m (up 179% from 2Q 2024). Net income: CN¥5.82m (up CN¥13.9m from 2Q 2024). Profit margin: 4.2% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jul 02
Jiangsu Sihuan Bioengineering Co., Ltd to Report First Half, 2025 Results on Aug 27, 2025 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report first half, 2025 results on Aug 27, 2025 Board Change • Jul 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-independent director Linfu Wei was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Jun 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Announcement • Jun 06
Jiangsu Sihuan Bioengineering Co., Ltd Announces Board Appointments Jiangsu Sihuan Bioengineering Co. Ltd. held its 2nd Extraordinary General Meeting of 2025 on 04 June 2025, approved: Change and election of directors; Qiu Weibi, non-independent director; Chen Long, non-independent director; Wei Linfu, non-independent director. Reported Earnings • Apr 30
Full year 2024 earnings released: CN¥0.11 loss per share (vs CN¥0.073 loss in FY 2023) Full year 2024 results: CN¥0.11 loss per share (further deteriorated from CN¥0.073 loss in FY 2023). Revenue: CN¥203.5m (down 14% from FY 2023). Net loss: CN¥110.0m (loss widened 46% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Apr 29
Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 21, 2025 Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 21, 2025, at 14:30 China Standard Time. Announcement • Mar 31
Jiangsu Sihuan Bioengineering Co., Ltd to Report Q1, 2025 Results on Apr 30, 2025 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Jan 16
Fujian Bishui Agricultural Investment Co., Ltd. completed the acquisition of 27.78% stake in Jiangsu Sihuan Bioengineering Co., Ltd (SZSE:000518) from Yu Qinfen, Wang Hongming, and Chen Jianguo. Fujian Bishui Agricultural Investment Co., Ltd. signed a letter of intent to acquire 27.78% stake in Jiangsu Sihuan Bioengineering Co., Ltd (SZSE:000518) from Yu Qinfen, Wang Hongming, and Chen Jianguo for approximately CNY 390 million on December 26, 2024. As of January 14, 2025, Fujian Bishui Agricultural Investment Co., Ltd. made the full payment.
Fujian Bishui Agricultural Investment Co., Ltd. completed the acquisition of 27.78% stake in Jiangsu Sihuan Bioengineering Co., Ltd (SZSE:000518) from Yu Qinfen, Wang Hongming, and Chen Jianguo on January 14, 2025. New Risk • Jan 12
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). New Risk • Jan 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 53% per year over the past 5 years. Announcement • Dec 31
Jiangsu Sihuan Bioengineering Co., Ltd to Report Fiscal Year 2024 Results on Apr 26, 2025 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report fiscal year 2024 results on Apr 26, 2025 New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Oct 30
Third quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.005 loss in 3Q 2023) Third quarter 2024 results: CN¥0.003 loss per share (improved from CN¥0.005 loss in 3Q 2023). Revenue: CN¥50.2m (down 14% from 3Q 2023). Net loss: CN¥3.56m (loss narrowed 36% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Jiangsu Sihuan Bioengineering Co., Ltd to Report Q3, 2024 Results on Oct 28, 2024 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report Q3, 2024 results on Oct 28, 2024 New Risk • Sep 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 47% per year over the past 5 years. Reported Earnings • Aug 31
Second quarter 2024 earnings released: CN¥0.008 loss per share (vs CN¥0.018 loss in 2Q 2023) Second quarter 2024 results: CN¥0.008 loss per share (improved from CN¥0.018 loss in 2Q 2023). Revenue: CN¥49.4m (down 23% from 2Q 2023). Net loss: CN¥8.09m (loss narrowed 57% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Jiangsu Sihuan Bioengineering Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report first half, 2024 results on Aug 27, 2024 Reported Earnings • May 01
First quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.018 loss in 1Q 2023) First quarter 2024 results: CN¥0.003 loss per share (improved from CN¥0.018 loss in 1Q 2023). Revenue: CN¥56.4m (down 1.1% from 1Q 2023). Net loss: CN¥2.97m (loss narrowed 84% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Announcement • May 01
Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 21, 2024 Jiangsu Sihuan Bioengineering Co., Ltd, Annual General Meeting, May 21, 2024, at 14:30 China Standard Time. Location: No. 6, Zhongfang, Xinyu Road, Xinqiao Town, Jiangyin, Jiangsu China Announcement • Mar 30
Jiangsu Sihuan Bioengineering Co., Ltd to Report Q1, 2024 Results on Apr 29, 2024 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report Q1, 2024 results on Apr 29, 2024 Announcement • Dec 29
Jiangsu Sihuan Bioengineering Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.008 loss in 3Q 2022) Third quarter 2023 results: CN¥0.005 loss per share (improved from CN¥0.008 loss in 3Q 2022). Revenue: CN¥58.5m (down 23% from 3Q 2022). Net loss: CN¥5.54m (loss narrowed 30% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 23
Second quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0.009 loss in 2Q 2022) Second quarter 2023 results: CN¥0.018 loss per share (further deteriorated from CN¥0.009 loss in 2Q 2022). Revenue: CN¥64.4m (down 5.4% from 2Q 2022). Net loss: CN¥18.8m (loss widened 95% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Board Change • Jul 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Liangwei Wu was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 01
Jiangsu Sihuan Bioengineering Co., Ltd to Report First Half, 2023 Results on Aug 23, 2023 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report first half, 2023 results on Aug 23, 2023 Announcement • Jun 28
Jiangsu Sihuan Bioengineering Co., Ltd Announces Directors Appointments Jiangsu Sihuan Bioengineering Co. Ltd. held its 1st Extraordinary General Meeting of 2023 on 26 June 2023 were approved election of Lu Yu as non-independent directors, Wu Liangwei and Wang Li as independent directors. Reported Earnings • Apr 28
Full year 2022 earnings released: CN¥0.047 loss per share (vs CN¥0.034 loss in FY 2021) Full year 2022 results: CN¥0.047 loss per share (further deteriorated from CN¥0.034 loss in FY 2021). Revenue: CN¥270.1m (down 23% from FY 2021). Net loss: CN¥48.8m (loss widened 40% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. Supervisor Xiao Li Gong is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 26
Third quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.005 profit in 3Q 2021) Third quarter 2022 results: CN¥0.002 loss per share (down from CN¥0.005 profit in 3Q 2021). Revenue: CN¥78.2m (down 9.5% from 3Q 2021). Net loss: CN¥2.43m (down 150% from profit in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 21
Second quarter 2022 earnings released: CN¥0.009 loss per share (vs CN¥0.014 loss in 2Q 2021) Second quarter 2022 results: CN¥0.009 loss per share (up from CN¥0.014 loss in 2Q 2021). Revenue: CN¥68.0m (down 14% from 2Q 2021). Net loss: CN¥9.65m (loss narrowed 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 28
Full year 2021 earnings released: CN¥0.034 loss per share (vs CN¥0.027 profit in FY 2020) Full year 2021 results: CN¥0.034 loss per share (down from CN¥0.027 profit in FY 2020). Revenue: CN¥351.0m (down 31% from FY 2020). Net loss: CN¥34.8m (down 228% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Non-Employee Representative Supervisor Jianrong Zhou is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 29
Second quarter 2021 earnings released: CN¥0.014 loss per share (vs CN¥0.004 loss in 2Q 2020) The company reported a poor second quarter result with increased losses and weaker control over costs, although revenues were flat. Second quarter 2021 results: Revenue: CN¥78.9m (flat on 2Q 2020). Net loss: CN¥14.4m (loss widened 259% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • May 02
First quarter 2021 earnings released: CN¥0.013 loss per share (vs CN¥0.01 profit in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: CN¥70.9m (down 55% from 1Q 2020). Net loss: CN¥13.3m (down 229% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 17
Full year 2020 earnings released: EPS CN¥0.027 (vs CN¥0.014 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥505.4m (up 21% from FY 2019). Net income: CN¥27.3m (up 91% from FY 2019). Profit margin: 5.4% (up from 3.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Mar 09
Jiangsu Sihuan Bioengineering Co., Ltd to Report Fiscal Year 2020 Results on Apr 17, 2021 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report fiscal year 2020 results on Apr 17, 2021 Is New 90 Day High Low • Feb 04
New 90-day low: CN¥4.07 The company is down 13% from its price of CN¥4.66 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. Is New 90 Day High Low • Jan 08
New 90-day high: CN¥5.48 The company is up 12% from its price of CN¥4.91 on 09 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period. Is New 90 Day High Low • Dec 17
New 90-day high: CN¥5.25 The company is up 11% from its price of CN¥4.74 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 02
New 90-day low: CN¥4.60 The company is down 33% from its price of CN¥6.89 on 04 August 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 21% over the same period. Announcement • Aug 13
Jiangsu Sihuan Bioengineering Co., Ltd to Report First Half, 2020 Results on Aug 29, 2020 Jiangsu Sihuan Bioengineering Co., Ltd announced that they will report first half, 2020 results on Aug 29, 2020 
